STOCK TITAN

Ocugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2025 Financial Results

Ocugen (NASDAQ: OCGN) will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, March 4, 2026 to discuss fourth quarter and full year 2025 financial results and provide a business update.

(Neutral)
(Neutral)
Tags
conferences earnings date

Ocugen (NASDAQ: OCGN) will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, March 4, 2026 to discuss fourth quarter and full year 2025 financial results and provide a business update.

A pre-market earnings announcement will be issued the same day. Dial-in numbers, conference ID, and a webcast link will be available on the company investor site; a replay and archived webcast will follow.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.
Argus Feb 18 session
+2.78% close to close Open Argus
Details

News Market Reaction – OCGN

On Feb 18, the day this news came out, OCGN closed 2.78% above the previous close.

Data tracked by StockTitan Argus for the Feb 18 session.

Market Context

This announcement schedules Ocugen’s Q4 and full‑year 2025 earnings call for March 4, 2026 at 8:30 a...
Analysis

This announcement schedules Ocugen’s Q4 and full‑year 2025 earnings call for March 4, 2026 at 8:30 a.m. ET, with results to post before the market opens. Historical data show five similar conferences/earnings notices with an average one‑day move of -0.55%, suggesting expectations around such updates have been measured. Investors may later compare the reported figures with recent financings, cash levels, and prior disclosures on losses and funding needs highlighted in recent SEC filings.

Key Figures

Conference date: March 4, 2026 Conference time: 8:30 a.m. ET U.S. dial-in: (800) 715-9871 +5 more
Conference date
March 4, 2026
Q4 and full year 2025 call
Conference time
8:30 a.m. ET
Earnings and business update call
U.S. dial-in
(800) 715-9871
Investor access number
International dial-in
(646) 307-1963
Investor access number
Conference ID
3029428
Call access code
Current price
$1.43
Prior to Q4 2025 call announcement
52-week range
$0.515 – $1.96
Pre-announcement trading range
Market cap
$461,521,358
Value before Q4 2025 earnings call notice

Previous Conferences,earnings Reports

5 past events · Latest: Oct 23
Same Type 5 events
  1. Oct 23

    Earnings call notice

    24h Move
    +1.3%

    Scheduled Q3 2025 call with pre-market earnings release.

  2. Jul 17

    Earnings call notice

    24h Move
    -3.9%

    Announced Q2 2025 earnings and business update call timing.

  3. May 02

    Earnings call notice

    24h Move
    +3.6%

    Set date for Q1 2025 financial results and update call.

  4. Feb 21

    Earnings call notice

    24h Move
    -2.9%

    Planned Q4 and full-year 2024 results and update webcast.

  5. Oct 17

    Earnings call notice

    24h Move
    -1.0%

    Announced Q3 2024 earnings call and business update timing.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

MALVERN, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company’s fourth quarter and full year 2025 financial results and provide a business update at 8:30 a.m. ET on Wednesday, March 4, 2026.

Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details:

Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callers
Conference ID: 3029428
Webcast: Available on the events section of the Ocugen investor site

A replay of the call and archived webcast will be available on the Ocugen investor site.

About Ocugen, Inc.
Ocugen, Inc. is a pioneering biotechnology leader in gene therapies for blindness diseases. Our breakthrough modifier gene therapy platform has the potential to address significant unmet medical need for large patient populations through our gene-agnostic approach. Unlike traditional gene therapies and gene editing, Ocugen’s modifier gene therapies address the entire disease—complex diseases that are potentially caused by imbalances in multiple gene networks. Currently we have programs in development for inherited retinal diseases and blindness diseases affecting millions across the globe, including retinitis pigmentosa, Stargardt disease, and geographic atrophy—late stage dry age-related macular degeneration. Discover more at www.ocugen.com and follow us on X and LinkedIn.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.

Contact:
Tiffany Hamilton
AVP, Head of Communications
Tiffany.Hamilton@ocugen.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Ocugen's (OCGN) conference call for Q4 and full year 2025 results?

The conference call is scheduled for 8:30 a.m. ET on Wednesday, March 4, 2026. According to the company, a pre-market earnings announcement will be released the same day and a live webcast will be available on the investor site.

How can investors join the Ocugen (OCGN) March 4, 2026 earnings webcast?

Investors can join via the live webcast on the company investor site events section. According to the company, dial-in numbers and a conference ID are also provided for telephone participation and a replay will be archived online.

What dial-in details does Ocugen (OCGN) provide for the March 4, 2026 call?

Ocugen provided U.S. dial-in (800) 715-9871 and international dial-in (646) 307-1963 with Conference ID 3029428. According to the company, callers should use these numbers and the conference ID to access the live call.

Will Ocugen (OCGN) make the March 4, 2026 call available after the live event?

Yes. A replay of the call and an archived webcast will be available on the investor site. According to the company, the archived materials will remain accessible after the live webcast for on-demand listening and review.

What will Ocugen (OCGN) cover during the March 4, 2026 conference call?

The call will discuss fourth quarter and full year 2025 financial results and provide a business update. According to the company, management will present results and offer commentary, followed by a Q&A session for participants.

Keep reading